Poor responders to controlled ovarian hyperstimulation for in vitro fertilisation (IVF)

References

• Akman M. A., Erden H. F., Tosun S. B., Bayazit N., Aksoy E., & Bahceci M. (2001). Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Human reproduction (Oxford, England), 16, 868–870.
   PubMed Web of Science ®Google Scholar
• Al-Inany H., Aboulghar M. A., Mansour R. T., & Serour G. I. (2005). Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology, 20, 161–169.
   PubMed Web of Science ®Google Scholar
• Anserini P., Magnasco A., Remorgida V., Gaggero G., Testa D., & Capitanio G. L. (1997). Comparison of a blocking vs. a flare-up protocol in poor responders with a normal and abnormal clomiphene citrate challenge test. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology, 11, 321–326.
   PubMed Web of Science ®Google Scholar
• Anteby, E. Y., Hurwitz, A., Korach, O., Revel, A., Simon, A., Finci-Yeheskel, Z., et al. (1996). Human follicular nitric oxide pathway: relationship to follicular size, oestradiol concentrations and ovarian blood flow. Human reproduction (Oxford, England), 11, 1947–1951.
   PubMed Web of Science ®Google Scholar
• Balasch, J., Fábregues, F., Peñarrubia, J., Carmona, F., Casamitjana, R., Creus, M., et al. (2006). Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Human reproduction (Oxford, England), 21, 1884–1893.
   PubMed Web of Science ®Google Scholar
• Battaglia C., Salvatori M., Maxia N., Petraglia F., Facchinetti F., & Volpe A. (1999). Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients. Human reproduction (Oxford, England), 14, 1690–1697.
   PubMed Web of Science ®Google Scholar
• Bergh C., Hillensjö T., Wikland M., Nilsson L., Borg G., & Hamberger L. (1994). Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study. Fertility and sterility, 62, 113–120.
   PubMed Web of Science ®Google Scholar
• Berkkanoglu M., Isikoglu M., Aydin D., & Ozgur K. (2007). Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertility and sterility, 88, 665–669.
   PubMed Web of Science ®Google Scholar
• Biljan, M. M., Hemmings, R., & Brassard N. (2005). The outcome of 150 babies following the treatment with letrozole and gonadotrophins. Fertility and Sterility, 84, S95.
   Web of Science ®Google Scholar
• Broekmans F. J., Knauff E. A., te Velde E. R., Macklon N. S., & Fauser B. C. (2007). Female reproductive ageing: current knowledge and future trends. Trends in endocrinology and metabolism: TEM, 18, 58–65.
   PubMed Web of Science ®Google Scholar
• Broekmans F. J., Kwee J., Hendriks D. J., Mol B. W., & Lambalk C. B. (2006). A systematic review of tests predicting ovarian reserve and IVF outcome. Human reproduction update, 12, 685–718.
   PubMed Web of Science ®Google Scholar
• Broekmans F. J., Soules M. R., & Fauser B. C. (2009). Ovarian aging: mechanisms and clinical consequences. Endocrine reviews, 30, 465–493.
   PubMed Web of Science ®Google Scholar
• Broer S. L., Mol B. W., Hendriks D., & Broekmans F. J. (2009). The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertility and sterility, 91, 705–714.
   PubMed Web of Science ®Google Scholar
• Brzyski R. G., Muasher S. J., Droesch K., Simonetti S., Jones G. S., & Rosenwaks Z. (1988). Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment. Fertility and sterility, 50, 917–921.
   PubMed Web of Science ®Google Scholar
• Cai, J., Lou, H. Y., Dong, M. Y., Lu, X. E., Zhu, Y. M., Gao, H. J., et al. (2007). Poor ovarian response to gonadotropin stimulation is associated with low expression of follicle-stimulating hormone receptor in granulosa cells. Fertility and sterility, 87, 1350–1356.
   PubMed Web of Science ®Google Scholar
• Centre for Clinical Effectiveness. (2000). In womenlabelled as poor responders to ovulation stimulation in an assisted reproduction program, is there evidence for the effectiveness of increasing the total dose of FSH above 3000 IU? Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2000:25, Cochrane Database, (2000). HTA-320030660.
   Google Scholar
• Cheung, L. P., Lam, P. M., Lok, I. H., Chiu, T. T., Yeung, S. Y., Tjer, C. C., et al. (2005). GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human reproduction (Oxford, England), 20, 616–621.
   PubMed Web of Science ®Google Scholar
• Chong A. P., Rafael R. W., & Forte C. C. (1986). Influence of weight in the induction of ovulation with human menopausal gonadotropin and human chorionic gonadotropin. Fertility and sterility, 46, 599–603.
   PubMed Web of Science ®Google Scholar
• D’Amato G., Caroppo E., Pasquadibisceglie A., Carone D., Vitti A., & Vizziello G. M. (2004). A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. Fertility and sterility, 81, 1572–1577.
   PubMed Web of Science ®Google Scholar
• De Placido, G., Alviggi, C., Mollo, A., Strina, I., Varricchio, M. T., & Molis M. (2000). Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Human reproduction (Oxford, England), 15, 17–20.
   PubMed Web of Science ®Google Scholar
• Delitala G., Tomasi P., & Virdis R. (1988). Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications. Journal of endocrinological investigation, 11, 441–462.
   PubMed Web of Science ®Google Scholar
• Detti L., Williams D. B., Robins J. C., Maxwell R. A., & Thomas M.. (2005). A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization. Fertility and sterility, 84, 1401–1405.
   PubMed Web of Science ®Google Scholar
• Dirnfeld, M., Fruchter, O., Yshai, D., Lissak, A., Ahdut, A., & Abramovici H. (1999). Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization. Fertility and sterility, 72, 406–411.
   PubMed Web of Science ®Google Scholar
• Doldi N., Bassan M., Bonzi V., & Ferrari A. (1996). Effects of growth hormone and growth hormone-releasing hormone on steroid synthesis in cultured human luteinizing granulosa cells. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology, 10, 101–108.
   PubMed Web of Science ®Google Scholar
• Domingues T. S., Rocha A. M., & Serafini P. C. (2010). Tests for ovarian reserve: reliability and utility. Current opinion in obstetrics & gynecology, 22, 271–276.
   PubMed Web of Science ®Google Scholar
• Droesch, K., Muasher, S. J., Brzyski, R. G., Jones, G. S., Simonetti, S., Liu, H. C., et al. (1989). Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization. Fertility and sterility, 51, 292–297.
   PubMed Web of Science ®Google Scholar
• Eskandar M., Jaroudi K., Jambi A., Archibong E. I., Coskun S., & Sobande A. A. (2004). Is recombinant follicle-stimulating hormone more effective in IVF poor responders than human menopausal gonadotrophins? Medical science monitor: international medical journal of experimental and clinical research, 10, PI6–PI9.
   PubMed Web of Science ®Google Scholar
• Faber, B. M., Mayer, J., Cox, B., Jones, D., Toner, J. P., Oehninger, S., et al. (1998). Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertility and sterility, 69, 826–830.
   PubMed Web of Science ®Google Scholar
• Fábregues, F., Peñarrubia, J., Creus, M., Manau, D., Casals, G., Carmona, F., et al. (2009). Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Human reproduction (Oxford, England), 24, 349–359.
   PubMed Web of Science ®Google Scholar
• Faddy, M. J. (2000). Follicle dynamics during ovarian ageing. Molecular and cellular endocrinology, 163, 43–48.
   PubMed Web of Science ®Google Scholar
• Faddy M. J., & Gosden R. G. (1996). A model conforming the decline in follicle numbers to the age of menopause in women. Human reproduction (Oxford, England), 11, 1484–1486.
   PubMed Web of Science ®Google Scholar
• Feldberg D., Farhi J., Ashkenazi J., Dicker D., Shalev J., & Ben-Rafael Z. (1994). Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertility and sterility, 62, 343–346.
   PubMed Web of Science ®Google Scholar
• Frattarelli, J. L., McWilliams, G. D., Hill, M. J., Miller, K. A., & Scott R. T. Jr. (2008). Low-dose aspirin use does not improve in vitro fertilization outcomes in poor responders. Fertility and sterility, 89, 1113–1117.
   PubMed Web of Science ®Google Scholar
• Fridén B. E., & Nilsson L.. (2005). Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta obstetricia et gynecologica Scandinavica, 84, 812–816.
   PubMed Web of Science ®Google Scholar
• Fridström M., Akerlöf E., Sjöblom P., & Hillensjö T.. (1997). Serum levels of luteinizing and follicle-stimulating hormones in normal and poor-responding patients undergoing ovarian stimulation with urofollitropin after pituitary downregulation. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology, 11, 25–28.
   PubMed Web of Science ®Google Scholar
• Garcia, J. E., Jones, G. S., Acosta, A. A., & Wright G. Jr. (1983). Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981. Fertility and sterility, 39, 174–179.
   PubMed Web of Science ®Google Scholar
• Garcia J. E., Padilla S. L., Bayati J., & @@@Baramki T. A. (1990). Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertility and sterility, 53, 302–305.
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco, J. A., Isaza, V., Requena, A., Martínez-Salazar, F. J., Landazábal, A., Remohí, J., et al. (2000). High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial. Human reproduction (Oxford, England), 15, 2292–2296.
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco, J. A., Moreno, L., Pacheco, A., Guillén, A., Duque, L., Requena, A., et al. (2005). The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertility and sterility, 84, 82–87.
   PubMed Web of Science ®Google Scholar
• Gibreel A., Maheshwari A., Bhattacharya S., & Johnson N. P. (2009). Ultrasound tests of ovarian reserve; a systematic review of accuracy in predicting fertility outcomes. Human fertility (Cambridge, England), 12, 95–106.
   PubMed Web of Science ®Google Scholar
• Gindoff P. R., Hall J. L., & Stillman R. J. (1990). Ovarian suppression with leuprolide acetate: comparison of luteal, follicular, and flare-up administration in controlled ovarian hyperstimulation for oocyte retrieval. Journal of in vitro fertilization and embryo transfer: IVF, 7, 94–97.
   PubMedGoogle Scholar
• Giudice, L. C. (1992). Insulin-like growth factors and ovarian follicular development. Endocrine reviews, 13, 641–669.
   PubMed Web of Science ®Google Scholar
• Gleicher, N. & Barad, D. (2006). The effect of dehydroepiandrosterone on diminished ovarian reserve. Human reproduction, 21 (Suppl 1), i69.
   Google Scholar
• Gordon U. D., Harrison R. F., Fawzy M., Hennelly B., & Gordon A. C. (2001). A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertility and sterility, 75, 324–331.
   PubMed Web of Science ®Google Scholar
• Goswami, S. K., Das, T., Chattopadhyay, R., Sawhney, V., Kumar, J., Chaudhury, K., et al. (2004). A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Human reproduction (Oxford, England), 19, 2031–2035.
   PubMed Web of Science ®Google Scholar
• Haller K., Salumets A., & Uibo, R. (2008). Anti-FSH antibodies associate with poor outcome of ovarian stimulation in IVF. Reproductive biomedicine online, 16, 350–355.
   PubMed Web of Science ®Google Scholar
• Hellberg D., Waldenström U., & Nilsson, S. (2004). Defining a poor responder in in vitro fertilization. Fertility and sterility, 82, 488–490.
   PubMed Web of Science ®Google Scholar
• Hendriks D. J., Mol B. W., Bancsi L. F., Te Velde E. R., & Broekmans F. J. (2005). Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertility and sterility, 83, 291–301.
   PubMed Web of Science ®Google Scholar
• Hendriks D. J., Mol B. W., Bancsi L. F., te Velde E. R., & Broekmans F. J. (2006). The clomiphene citrate challenge test for the prediction of poor ovarian response and nonpregnancy in patients undergoing in vitro fertilization: a systematic review. Fertility and sterility, 86, 807–818.
   PubMed Web of Science ®Google Scholar
• Hendriks D. J., Kwee J., Mol B. W., te Velde E. R., & Broekmans F. J. (2007). Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertility and sterility, 87, 764–775.
   PubMed Web of Science ®Google Scholar
• Hernandez, E. R., Hurwitz, A., Vera, A., Pellicer, A., Adashi, E. Y., LeRoith, D., et al. (1992). Expression of the genes encoding the insulin-like growth factors and their receptors in the human ovary. The Journal of clinical endocrinology and metabolism, 74, 419–425.
   PubMed Web of Science ®Google Scholar
• Homburg R., & Farhi, J. (1995). Growth hormone and reproduction. Current opinion in obstetrics & gynecology, 7, 220–223.
   PubMed Web of Science ®Google Scholar
• Homburg R., Eshel A., Abdalla H. I., & Jacobs H. S. (1988). Growth hormone facilitates ovulation induction by gonadotrophins. Clinical endocrinology, 29, 113–117.
   PubMed Web of Science ®Google Scholar
• Horie K., Takakura K., Fujiwara H., Suginami H., Liao S., & Mori T. (1992). Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Human reproduction (Oxford, England), 7, 184–190.
   PubMed Web of Science ®Google Scholar
• Horvath P. M., Styler M., Hammond J. M., Shelden R. M., & Kemmann E. (1988). Exogenous gonadotropin requirements are increased in leuprolide suppressed women undergoing ovarian stimulation. Fertility and sterility, 49, 159–162.
   PubMed Web of Science ®Google Scholar
• Howles, C. M., Loumaye, E., Germond, M., Yates, R., Brinsden, P., Healy, D., et al. (1999). Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization? Human reproduction (Oxford, England), 14, 1939–1943.
   PubMed Web of Science ®Google Scholar
• Hughes S. M., Huang Z. H., Morris I. D., Matson P. L., Buck P., & Lieberman B. A. (1994). A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in-vitro fertilization. Human reproduction (Oxford, England), 9, 13–18.
   PubMed Web of Science ®Google Scholar
• Jia X. C., Kalmijn J., & Hsueh A. J. (1986). Growth hormone enhances follicle-stimulating hormone-induced differentiation of cultured rat granulosa cells. Endocrinology, 118, 1401–1409.
   PubMed Web of Science ®Google Scholar
• Kailasam C., Keay S. D., Wilson P., Ford W. C., & Jenkins J. M. (2004). Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome. Human reproduction (Oxford, England), 19, 1544–1547.
   PubMed Web of Science ®Google Scholar
• Jayaprakasan K., Campbell B., Hopkisson J., Johnson I., & Raine-Fenning N. (2010). A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertility and sterility, 93, 855–864.
   PubMed Web of Science ®Google Scholar
• Jayaprakasan, K., Al-Hasie, H., Jayaprakasan, R., Campbell, B., Hopkisson, J., Johnson, I., et al. (2009). The three-dimensional ultrasonographic ovarian vascularity of women developing poor ovarian response during assisted reproduction treatment and its predictive value. Fertility and sterility, 92, 1862–1869.
   PubMed Web of Science ®Google Scholar
• Kansal Kalra S., Ratcliffe S., Gracia C. R., Martino L., Coutifaris C., & Barnhart K. T. (2008). Randomized controlled pilot trial of luteal phase recombinant FSH stimulation in poor responders. Reproductive biomedicine online, 17, 745–750.
   PubMed Web of Science ®Google Scholar
• Karande V. C., Jones G. S., Veeck L. L., & Muasher S. J. (1990). High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertility and sterility, 53, 486–489.
   PubMed Web of Science ®Google Scholar
• Karande V., Morris R., Rinehart J., Miller C., Rao R., & Gleicher N. (1997). Limited success using the “flare” protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization. Fertility and sterility, 67, 900–903.
   PubMed Web of Science ®Google Scholar
• Katayama K. P., Roesler M., Gunnarson C., Stehlik E., & Jagusch S. (1988). Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization. Journal of in vitro fertilization and embryo transfer: IVF, 5, 332–334.
   PubMedGoogle Scholar
• Keay S. D., Liversedge N. H., & Jenkins J. M. (1998). Could ovarian infection impair ovarian response to gonadotrophin stimulation? British journal of obstetrics and gynaecology, 105, 252–253.
   PubMedGoogle Scholar
• Keay S. D., Liversedge N. H., Mathur R. S., & Jenkins J. M. (1997). Assisted conception following poor ovarian response to gonadotrophin stimulation. British journal of obstetrics and gynaecology, 104, 521–527.
   PubMedGoogle Scholar
• Kim C. H., Chae H. D., & Chang Y. S. (1999). Pyridostigmine cotreatment for controlled ovarian hyperstimulation in low responders undergoing in vitro fertilization-embryo transfer. Fertility and sterility, 71, 652–657.
   PubMed Web of Science ®Google Scholar
• Kim C. H., Howles C. M., & Lee H. A. (2011). The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertility and sterility, 95, 679–683.
   PubMed Web of Science ®Google Scholar
• Klinkert E. R., Broekmans F. J., Looman C. W., Habbema J. D., &teVelde E.R.. (2005). Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human reproduction (Oxford, England), 20, 611–615.
   PubMed Web of Science ®Google Scholar
• Kolibianakis E. M., Venetis C. A., Diedrich K., Tarlatzis B. C., & Griesinger G. (2009). Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Human reproduction update, 15, 613–622.
   PubMed Web of Science ®Google Scholar
• Kucuk T., & Sozen E. (2007). Luteal start of exogenous FSH in poor responder women. Journal of assisted reproduction and genetics, 24, 635–638.
   PubMed Web of Science ®Google Scholar
• Kupesic S., Kurjak A., Bjelos D., & Vujisic S. (2003). Three-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age. Fertility and sterility, 79, 190–197.
   PubMed Web of Science ®Google Scholar
• Kyrou D., Kolibianakis E. M., Venetis C. A., Papanikolaou E. G., Bontis J., & Tarlatzis B. C. (2009). How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertility and sterility, 91, 749–766.
   PubMed Web of Science ®Google Scholar
• La Marca, A., Sighinolfi, G., Radi, D., Argento, C., Baraldi, E., Artenisio, A. C., et al. (2010). Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Human reproduction update, 16, 113–130.
   PubMed Web of Science ®Google Scholar
• Land J. A., Yarmolinskaya M. I., Dumoulin J. C., & Evers J. L. (1996). High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertility and sterility, 65, 961–965.
   PubMed Web of Science ®Google Scholar
• Lanzone A., Di Simone N., Castellani R., Fulghesu A. M., Caruso A., & Mancuso S. (1992). Human growth hormone enhances progesterone production by human luteal cells in vitro: evidence of a synergistic effect with human chorionic gonadotropin. Fertility and sterility, 57, 92–96.
   PubMed Web of Science ®Google Scholar
• Lee, D. W., Grasso, P., Dattatreyamurty, B., Deziel, M. R., & Reichert L. E. Jr. (1993). Purification of a high molecular weight follicle-stimulating hormone receptor-binding inhibitor from human follicular fluid. The Journal of clinical endocrinology and metabolism, 77, 163–168.
   PubMed Web of Science ®Google Scholar
• Lekamge D. N., Lane M., Gilchrist R. B., & Tremellen K. P. (2008). Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. Journal of assisted reproduction and genetics, 25, 515–521.
   PubMed Web of Science ®Google Scholar
• Loh S., Wang J. X., & Matthews C. D. (2002). The influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients. Human reproduction (Oxford, England), 17, 1207–1211.
   PubMed Web of Science ®Google Scholar
• Lok I. H., Yip S. K., Cheung L. P., Yin Leung P. H., & Haines C. J. (2004). Adjuvant low-dose aspirin therapy in poor responders undergoing in vitro fertilization: a prospective, randomized, double-blind, placebo-controlled trial. Fertility and sterility, 81, 556–561.
   PubMed Web of Science ®Google Scholar
• Loutradis, D., Patsoula, E., Minas, V., Koussidis, G. A., Antsaklis, A., Michalas, S., et al. (2006). FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. Journal of assisted reproduction and genetics, 23, 177–184.
   PubMed Web of Science ®Google Scholar
• Loutradis D., Vomvolaki E., & Drakakis P. (2008). Poor responder protocols for in-vitro fertilization: options and results. Current opinion in obstetrics & gynecology, 20, 374–378.
   PubMed Web of Science ®Google Scholar
• Maheshwari A., Gibreel A., Bhattacharya S., & Johnson N. P. (2009). Dynamic tests of ovarian reserve: a systematic review of diagnostic accuracy. Reproductive biomedicine online, 18, 717–734.
   PubMed Web of Science ®Google Scholar
• Malmusi, S., La Marca, A., Giulini, S., Xella, S., Tagliasacchi, D., Marsella, T., et al. (2005). Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertility and sterility, 84, 402–406.
   PubMed Web of Science ®Google Scholar
• Marci R., Caserta D., Dolo V., Tatone C., Pavan A., & Moscarini M. (2005). GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reproductive biomedicine online, 11, 189–193.
   PubMed Web of Science ®Google Scholar
• Martinez, F., Barri, P. N., Coroleu, B., Tur, R., Sorsa-Leslie, T., Harris, W. J., et al. (2002). Women with poor response to IVF have lowered circulating gonadotrophin surge-attenuating factor (GnSAF) bioactivity during spontaneous and stimulated cycles. Human reproduction (Oxford, England), 17, 634–640.
   PubMed Web of Science ®Google Scholar
• Massin N., Cedrin-Durnerin I., Coussieu C., Galey-Fontaine J., Wolf J. P., & Hugues J. N. (2006). Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique–a prospective, randomized, double-blind study. Human reproduction (Oxford, England), 21, 1204–1211.
   PubMedGoogle Scholar
• Mochtar M. H., Van der Veen Ziech M. & van Wely M. (2007). Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane database of systematic reviews (Online), 18(2): CD005070.
   Google Scholar
• Mohiyiddeen L., & Nardo L. G. (2010). Single-nucleotide polymorphisms in the FSH receptor gene and ovarian performance: future role in IVF. Human fertility (Cambridge, England), 13, 72–78.
   PubMed Web of Science ®Google Scholar
• Moncada S., Palmer R. M., & Higgs E. A. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological reviews, 43, 109–142.
   PubMed Web of Science ®Google Scholar
• Moreno C., Ruiz A., Simón C., Pellicer A., & Remohí J. (1998). Intracytoplasmic sperm injection as a routine indication in low responder patients. Human reproduction (Oxford, England), 13, 2126–2129.
   PubMed Web of Science ®Google Scholar
• Morgia, F., Sbracia, M., Schimberni, M., Giallonardo, A., Piscitelli, C., Giannini, P., et al. (2004). A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization. Fertility and sterility, 81, 1542–1547.
   PubMed Web of Science ®Google Scholar
• Muttukrishna S., McGarrigle H., Wakim R., Khadum I., Ranieri D. M., & Serhal P. (2005). Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG: an international journal of obstetrics and gynaecology, 112, 1384–1390.
   PubMed Web of Science ®Google Scholar
• Nargund G., & Bromhan D. (1995). Comparison of endocrinological and clinical profiles and outcome of IVF cycles in patients with one ovary and two ovaries. Journal of assisted reproduction and genetics, 12, 458–460.
   PubMed Web of Science ®Google Scholar
• Nelson S. M., Yates R. W., & Fleming R. (2007). Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles–implications for individualization of therapy. Human reproduction (Oxford, England), 22, 2414–2421.
   PubMed Web of Science ®Google Scholar
• Nelson, S. M., Yates, R. W., Lyall, H., Jamieson, M., Traynor, I., Gaudoin, M., et al. (2009). Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Human reproduction (Oxford, England), 24, 867–875.
   PubMed Web of Science ®Google Scholar
• Nilsson L., Andersen A. N., Lindenberg S., Hausken J., Andersen C. Y., & Kahn J. A. (2010). Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter ‘extended pilot study’. Acta obstetricia et gynecologica Scandinavica, 89, 828–831.
   PubMed Web of Science ®Google Scholar
• Olivennes, F., Righini, C., Fanchin, R., Torrisi, C., Hazout, A., Glissant, M., et al. (1996). A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. Human reproduction (Oxford, England), 11, 1169–1172.
   PubMed Web of Science ®Google Scholar
• Padilla S. L., Dugan K., Maruschak V., Shalika S., & Smith R. D. (1996). Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertility and sterility, 65, 796–799.
   PubMed Web of Science ®Google Scholar
• Palter S. F., Tavares A. B., Hourvitz A., Veldhuis J. D., & Adashi E. Y. (2001). Are estrogens of import to primate/human ovarian folliculogenesis? Endocrine reviews, 22, 389–424.
   PubMed Web of Science ®Google Scholar
• Pan H. A., Cheng Y. C., Li C. H., Wu M. H., & Chang F. M. (2002). Ovarian stroma flow intensity decreases by age: a three-dimensional power doppler ultrasonographic study. Ultrasound in medicine & biology, 28, 425–430.
   PubMed Web of Science ®Google Scholar
• Pandey S., Pandey S., Maheshwari A., & Bhattacharya. (2010). The impact of female obesity on the outcome of fertility treatment. Journal of human reproductive sciences, 3, 62–67.
   PubMedGoogle Scholar
• Pandian, Z., McTavish, A. R., Aucott, L., Hamilton, M. P., &Bhattacharya, S. (2010). Interventions for ‘poor responders’ to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database of Systematic Reviews, 20, CD004379.
   Google Scholar
• Pellicer A., Ardiles G., Neuspiller F., Remohí J., Simón C., & Bonilla-Musoles F. (1998). Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle-stimulating hormone using three-dimensional ultrasonography. Fertility and sterility, 70, 671–675.
   PubMed Web of Science ®Google Scholar
• Pellicer, A., Ballester, M. J., Serrano, M. D., Mir, A., Serra-Serra, V., Remohi, J., et al. (1994). Aetiological factors involved in the low response to gonadotrophins in infertile women with normal basal serum follicle stimulating hormone levels. Human reproduction (Oxford, England), 9, 806–811.
   PubMed Web of Science ®Google Scholar
• Perez Mayorga M., Gromoll J., Behre H. M., Gassner C., Nieschlag E., & Simoni M. (2000). Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. The Journal of clinical endocrinology and metabolism, 85, 3365–3369.
   PubMed Web of Science ®Google Scholar
• Pru J. K., & Tilly J. L. (2001). Programmed cell death in the ovary: insights and future prospects using genetic technologies. Molecular endocrinology (Baltimore, Md.), 15, 845–853.
   PubMedGoogle Scholar
• Raga F., Bonilla-Musoles F., Casañ E. M., & Bonilla F. (1999). Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome. Human reproduction (Oxford, England), 14, 1431–1434.
   PubMed Web of Science ®Google Scholar
• Rombauts L., Suikkari A. M., MacLachlan V., Trounson A. O., & Healy D. L. (1998). Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle. Fertility and sterility, 69, 665–669.
   PubMed Web of Science ®Google Scholar
• Rosencrantz M. A., Wachs D. S., Coffler M. S., Malcom P. J., Donohue M., & Chang R. J. (2010). Comparison of inhibin B and estradiol responses to intravenous FSH in women with polycystic ovary syndrome and normal women. Human reproduction (Oxford, England), 25, 198–203.
   PubMed Web of Science ®Google Scholar
• Schmidt D. W., Bremner T., Orris J. J., Maier D. B., Benadiva C. A., & Nulsen J. C. (2005). A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertility and sterility, 83, 1568–1571.
   PubMed Web of Science ®Google Scholar
• Schoolcraft W., Schlenker T., Gee M., Stevens J., & Wagley L. (1997). Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertility and sterility, 67, 93–97.
   PubMed Web of Science ®Google Scholar
• Schoolcraft, W. B., Surrey, E. S., Minjarez, D. A., Stevens, J. M., & Gardner D. K. (2008). Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol? Fertility and sterility, 89, 151–156.
   PubMed Web of Science ®Google Scholar
• Scott R. T., & Navot D. (1994). Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertility and sterility, 61, 880–885.
   PubMed Web of Science ®Google Scholar
• Seifer D. B., Lambert-Messerlian G., Hogan J. W., Gardiner A. C., Blazar A. S., & Berk C. A. (1997). Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertility and sterility, 67, 110–114.
   PubMed Web of Science ®Google Scholar
• Sills E. S., Alper M. M., & Walsh A. P. (2009). Ovarian reserve screening in infertility: practical applications and theoretical directions for research. European journal of obstetrics, gynecology, and reproductive biology, 146, 30–36.
   PubMed Web of Science ®Google Scholar
• Simon Brown. May 2010; Poor ovarian response: from the ‘unknown’ to consensus in definition and prognostic tests. Focus on Reproduction 24–25; ESHRE Special Interest Group− Multidisciplinary Consensus Meeting.
   Google Scholar
• Simoni M., Gromoll J., & Nieschlag E. (1997). The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocrine reviews, 18, 739–773.
   PubMed Web of Science ®Google Scholar
• Simoni M., Nieschlag E., & Gromoll J. (2002). Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Human reproduction update, 8, 413–421.
   PubMed Web of Science ®Google Scholar
• Sladkevicius P., Valentin L., & Marsá I.K. (1993). Blood flow velocity in the uterine and ovarian arteries during the normal menstrual cycle. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 3, 199–208.
   PubMed Web of Science ®Google Scholar
• Smulders, B., van Oirschot, S. M., Farquhar, C., Rombauts, L., &Kremer, J. A. (2010). Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews, 20, CD006109.
   Google Scholar
• Spandorfer S., Navarro J., Kump L. M., Liu H. C., Davis O. K., & Rosenwaks Z. (2001). “Co-Flare” stimulation in the poor responder patient: predictive value of the flare response. Journal of assisted reproduction and genetics, 18, 629–633.
   PubMed Web of Science ®Google Scholar
• Surrey E. S., Bower J., Hill D. M., Ramsey J., & Surrey M. W. (1998). Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertility and sterility, 69, 419–424.
   PubMed Web of Science ®Google Scholar
• Surrey, E. S. (2007). Management of the poor responder: the role of GnRH agonists and antagonists. Journal of assisted reproduction and genetics, 24, 613–619.
   PubMed Web of Science ®Google Scholar
• Suzuki, T., Sasano, H., Kimura, N., Tamura, M., Fukaya, T., Yajima, A., et al. (1994). Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Human reproduction (Oxford, England), 9, 1589–1595.
   PubMed Web of Science ®Google Scholar
• Tarlatzis B. C., Zepiridis L., Grimbizis G., & Bontis J. (2003). Clinical management of low ovarian response to stimulation for IVF: a systematic review. Human reproduction update, 9, 61–76.
   PubMed Web of Science ®Google Scholar
• Templeton A., Morris J. K., & Parslow W. (1996). Factors that affect outcome of in-vitro fertilisation treatment. Lancet, 348, 1402–1406.
   PubMed Web of Science ®Google Scholar
• Tesarik, J., Hazout, A., & Mendoza C. (2005). Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone. Human reproduction (Oxford, England), 20, 2536–2541.
   PubMed Web of Science ®Google Scholar
• Toth T. L., Awwad J. T., Veeck L. L., Jones H. W. Jr, & Muasher S. J. (1996). Suppression and flare regimens of gonadotropin-releasing hormone agonist. Use in women with different basal gonadotropin values in an in vitro fertilization program. The Journal of reproductive medicine, 41, 321–326.
   PubMed Web of Science ®Google Scholar
• Tulandi, T., Martin, J., Al-Fadhli, R., Kabli, N., Forman, R., Hitkari, J., et al. (2006). Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertility and sterility, 85, 1761–1765.
   PubMed Web of Science ®Google Scholar
• Ubaldi, F. (2010). Poor ovarian response: from the ‘unknown’ to consensus in definition and prognostic tests. Focus on Reproduction 24–25; ESHRE Special Interest Group− Multidisciplinary Consensus Meeting.
   Google Scholar
• van Rooij, I. A., Broekmans, F. J., te Velde, E. R., Fauser, B. C., Bancsi, L. F., de Jong, F. H., et al. (2002). Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Human reproduction (Oxford, England), 17, 3065–3071.
   PubMed Web of Science ®Google Scholar
• Weenen, C., Laven, J. S., Von Bergh, A. R., Cranfield, M., Groome, N. P., Visser, J. A., et al. (2004). Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Molecular human reproduction, 10, 77–83.
   PubMed Web of Science ®Google Scholar
• Weissman A., Farhi J., Royburt M., Nahum H., Glezerman M., & Levran D. (2003). Prospective evaluation of two stimulation protocols for low responders who were undergoing in vitro fertilization-embryo transfer. Fertility and sterility, 79, 886–892.
   PubMed Web of Science ®Google Scholar
• Yarali H., Esinler I., Polat M., Bozdag G., & Tiras B. (2009). Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol. Fertility and sterility, 92, 231–235.
   PubMed Web of Science ®Google Scholar
• Younis, J. S., Jadaon, J., Izhaki, I., Haddad, S., Radin, O., Bar-Ami, S., et al. (2010). A simple multivariate score could predict ovarian reserve, as well as pregnancy rate, in infertile women. Fertility and sterility, 94, 655–661.
   PubMed Web of Science ®Google Scholar
• Zaidi J., Barber J., Kyei-Mensah A., Bekir J., Campbell S., & Tan S. L. (1996). Relationship of ovarian stromal blood flow at the baseline ultrasound scan to subsequent follicular response in an in vitro fertilization program. Obstetrics and gynecology, 88, 779–784.
   PubMed Web of Science ®Google Scholar
• Zeleznik, A. J., Schuler, H. M., & Reichert L. E. Jr. (1981). Gonadotropin-binding sites in the rhesus monkey ovary: role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle. Endocrinology, 109, 356–362.
   PubMed Web of Science ®Google Scholar